This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
The objective is to balance the accounts from 2014, saving more than 8 million per year
The Instituto de Salud Carlos III has committed an extra 4 million
The Spanish National Cancer Research Centre (CNIO) Board of Trustees has today updated its Viability Plan, which includes new measures aimed at saving over 8 million per year from 2014 to 2016. In so doing, the budgetary imbalance is expected to be corrected.
The CNIO Viability Plan, which was approved at the end of 2012, has allowed the institution to save up to 3 million. Nevertheless, this year the Centre is facing a budget deficit of 8 million euros, which explains the need for the approval of new austerity measures aimed at maintaining the level of excellence which has allowed the centre to become a global benchmark for cancer research.
The budget imbalance is the consequence of an unexpected drop in funding. To correct the financial deficit in 2013, an extra 4 million euros will be provided by the Instituto de Salud Carlos III (ISCIII).
In parallel, new cost-cutting measures will be implemented, including a reduction in operating costs, procurement costs and personnel. Specifically, it is expected that around 36 temporary contracts will not be renewed, and 28 members of staff will be made redundant, out of a total of 470 employees (430 of which are researchers). The reduction in the workforce will be negotiated jointly with the CNIO Works Council.
The cost of salaries will be reduced through the elimination of bonuses and extras, salary reductions among executive roles, as well as a set of flexibility measures for employees.
As regards operating costs, additional measures will be taken, such as the operational integration of services shared with other bodies belonging to the ISCIII, following the recommendations of the Government’s Reform Programme.
These measures will not involve a decrease in the Centre’s scientific activity nor the removal of research groups, allowing the Centre to maintain the level of excellence and its privileged position as a top research centre in oncology around the world. These measures will let the Centre continue taking on scientific challenges and attracting talent.
The execution of the Viability Plan will be supervised by the Monitoring Committee, made up of ISCIII experts, the State Secretariat for Research and private trustees. This Committee will guarantee incomes and outgoings evolved as expected and will inform the Executive Committee.